Generation of small 32P-labeled peptides as a potential approach to colorectal cancer therapy

John M. Abraham, Yulan Cheng, James P. Hamilton, Bogdan Paun, Zhe Jin, Rachana Agarwal, Takatsugu Kan, Stefan David, Alexandru Olaru, Jian Yang, Tetsuo Ito, Florin M. Selaru, Yuriko Mori, Stephen J. Meltzer

Research output: Contribution to journalArticlepeer-review


Cancers have been revealed to be extremely heterogenous in terms of the frequency and types of mutations present in cells from different malignant tumors. Thus, it is likely that uniform clinical treatment is not optimal for all patients, and that the development of individualized therapeutic regimens may be beneficial. We describe the generation of multiple, unique small peptides nine to thirty-four amino acids in length which, when labeled with the radioisotope 32P, bind with vastly differing efficiencies to cell lines derived from different colon adenocarcinomas. In addition, the most effective of these peptides permanently transfers the 32P radioisotope to colorectal cancer cellular proteins within two hours at a rate that is more than 150 times higher than in cell lines derived from other cancers or from the normal tissues tested. Currently, the only two FDA-approved radioimmunotherapeutic agents in use both employ antibodies directed against the B cell marker CD20 for the treatment of non-Hodgkin's lymphoma. By using the method described herein, large numbers of different 32P-labeled peptides can be readily produced and assayed against a broad spectrum of cancer types. This report proposes the development and use of 32P-labeled peptides as potential individualized peptide-binding therapies for the treatment of colon adenocarcinoma patients.

Original languageEnglish (US)
Article numbere2508
JournalPloS one
Issue number6
StatePublished - Jun 25 2008

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General


Dive into the research topics of 'Generation of small 32P-labeled peptides as a potential approach to colorectal cancer therapy'. Together they form a unique fingerprint.

Cite this